Page 7,136«..1020..7,1357,1367,1377,138..7,1507,160..»

When nerve meets muscle, biglycan seals the deal

Posted: Published on February 14th, 2012

The protein biglycan needs to be present to stabilize synapses at the neuromuscular junction after they have formed, according to research led by Brown University that appears in the Feb. 14, 2012, issue of the Journal of Neruoscience. "What neuromuscular junctions do second-by-second is essential for our brain to control movement and they are also important for the long-term health of both muscle and motor neurons," said Justin Fallon, profesor of neuroscience at Brown University and the paper's senior author. "A treatment that sustains or supports the synapse could promote the health of motor neurons and muscle." In previous work, Fallon, a member of the Brown Institute for Brain Science, has shown that in mice with the same genetic mutation as Duchenne patients, biglycan promotes the activity of another natural protein, utrophin, that can significantly reduce the muscle degradation that patients suffer. Utrophin essentially takes over for dystrophin, which is the protein Duchenne patients cannot produce. In 2010 Brown licensed Fallon's biglycan intellectual property to the Providence startup company Tivorsan Pharmaceuticals, which is working toward human trials of biglycan. Last month the Muscular Dystrophy Association, which helped support Fallon's new study, gave Tivorsan a $1 million grant. Now Fallon's research … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on When nerve meets muscle, biglycan seals the deal

JumpStart Invests $250,000 in Milo Biotechnology

Posted: Published on February 14th, 2012

CLEVELAND, Feb. 14, 2012 /PRNewswire/ -- Milo Biotechnology will receive $250,000 from JumpStart Inc., a nonprofit investing intensive business assistance and some capital into early stage Northeast Ohio-based tech companies.  A clinical stage startup developing a therapy to increase muscle strength and improve the quality of life of muscular dystrophy patients, Milo is the 61st company in JumpStart's portfolio.  "There are limited treatment options for muscular dystrophy and approved therapies are inadequate or can cause significant side effects," says JumpStart's Mike Lang. "Since most muscular dystrophy patients are children, the medical community is interested in a safer and more targeted therapy." Milo Biotechnology's lead product is an adeno-associated virus (AAV) delivered follistatin protein.  Follistatin inhibits the activity of myostatin, a protein that impedes muscle differentiation and growth.  That makes follistatin a very potent stimulator of muscle growth and prevention of muscle scarring after injury.  "The translational research team at the Research Institute at Nationwide Children's Hospital has harnessed the power of follistatin and increased its specificity for muscle," explains Al Hawkins, CEO of Milo Biotechnology and CEO-in-Residence at BioEnterprise in Cleveland. "The efficacy and safety results thus far have been remarkable." Pre-clinical studies in mice and non-human primates demonstrated considerable increases … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on JumpStart Invests $250,000 in Milo Biotechnology

Possible link to hyper-excitability factors in epilepsy, autism and more

Posted: Published on February 14th, 2012

ScienceDaily (Feb. 14, 2012) — A UT Dallas undergraduate's research is revealing new information about a key protein's role in the development of epilepsy, autism and other neurological disorders. This work could one day lead to new treatments for the conditions. Senior neuroscience student Francisco Garcia has worked closely with Dr. Marco Atzori, associate professor in the School of Behavioral and Brain Sciences (BBS), on several papers that outline their findings about interleukin 6 (IL-6) and hyper-excitability. An article on the project is slated for publication in Biological Psychiatry later this year. Scientists know that stress elevates the levels of pro-inflammatory cytokines (signaling molecules used in intercellular communication) and promotes hyper-excitable conditions within the central nervous system. This hyper-excitability is thought to be a factor in epilepsy, autism and anxiety disorders. Garcia and Atzori hypothesized that the protein IL-6 acutely and directly induces hyper-excitability by altering the balance between excitation and inhibition within synaptic communication. In other words, IL-6 is not just present when hyper-excitability occurs in the nervous system. It may actually cause it in some circumstances, Garcia said. The UT Dallas research team administered IL-6 to rat brain tissue and monitored its synaptic excitability. The brain tissue exhibited … Continue reading

Comments Off on Possible link to hyper-excitability factors in epilepsy, autism and more

Utah House GOP reaches a deal on autism coverage

Posted: Published on February 14th, 2012

A deal struck after weeks of negotiations among House Republican leaders could extend coverage for treatment of about 800 children with autism, but would stop short of a more sweeping and contentious mandate. “We believe this is a Utah solution to addressing autism,” said House Assistant Majority Whip Ronda Menlove, R-Garland, who had sponsored the bill requiring about a third of Utah’s insurance carriers to cover autism treatment. Under terms of the deal, which will be contained in HB272, the state would set up a two-year pilot program within the health plan that covers public employees, which would extend coverage to a few hundred children. The state would then put about $2 million toward covering low-income children through Medicaid, which would be matched by several million in federal funds to cover about 500 children. Then, private commercial carriers, corporations and others have agreed to kick in about another $2 million to a state fund that would enable the treatment of few hundred others. Children between ages 2 and 6 would qualify for the benefits. “It will not help everyone universally,” said House Majority Whip Greg Hughes, R-Draper. “But we’ve been told that early intervention is critical in terms of costs … Continue reading

Comments Off on Utah House GOP reaches a deal on autism coverage

CFT: North Texas' McCarney suffered stroke

Posted: Published on February 14th, 2012

AP UPDATED 2/14/2012 @ 3:27 p.m. ET: North Texas head coach Dan McCarney confirmed to the Des Moines Register that he had indeed suffered a stroke over the weekend.  McCarney told the paper that, after his daily workout Sunday morning, he “was just sitting down to eat a sandwich when my left side went numb.” He remains hospitalized, but doctors told him he’s fine and that “[t]hey’re expecting a full recovery – no permanent damage.”  The health issue should not prevent McCarney from coaching his team in spring practice. As for the steps he will take to get beyond the medical setback and ensure his presence at the sessions? “Nothing wrong with me that a little Grey Goose won’t cure,” the 58-year-old coach said, quickly becoming the leader in the clubhouse for inspirational quote of the year in college football. In a press release issued Tuesday afternoon, UNT confirmed that McCarney has been moved out of ICU and will continue to undergo medical treatment.  A statement from McCarney was also included in the release: First, thanks to all the wonderful people who sent well-wishes during my time of illness.  I am reminded of how truly blessed I am by the … Continue reading

Comments Off on CFT: North Texas' McCarney suffered stroke

UNT's McCarney confirms stroke, expects recovery

Posted: Published on February 14th, 2012

DENTON, Texas (AP)—North Texas coach Dan McCarney said Tuesday that he suffered a stroke over the weekend and expects to recover in time to lead his team through spring drills. McCarney said in a statement provided by the school that he felt his left side go numb Sunday and was taken to a hospital. Doctors later confirmed he had a stroke. McCarney, 58, is out of intensive care but remained in the hospital Tuesday for further treatment. He said he expected to be back to his normal routine “in time.” The team starts spring practice March 28. “While I have a great passion for coaching and approach my job with a tireless effort, I’m sure that my doctors will ask that I come back at a slower pace,” he said. “I fully intend on leading the North Texas football program through spring drills and can’t wait to be back around my staff and players.” McCarney told the Denton Record-Chronicle that he had finished a workout and was sending a text message when he felt numbness. “There was a blood clot that hit the back of my brain,” McCarney told the newspaper. “My son Shane and my wife were there. We … Continue reading

Comments Off on UNT's McCarney confirms stroke, expects recovery

Moderate Air Pollution Linked To Stroke, Cognitive Decline

Posted: Published on February 14th, 2012

Chronic exposure to air pollution, even at levels typically considered safe by federal regulations, increases the risk of stroke by 34 percent and may accelerate cognitive decline in older adults, according to two separate studies published this week in the Archives of Internal Medicine. In one study, researchers studied more than 1,700 stroke patients in the Boston area over a 10-year period, and found exposure to ambient fine particulate matter (PM), generally from vehicle traffic, was associated with a significantly higher risk of ischemic strokes on days when the EPA’s air quality index for PM was yellow instead of green. The researchers focused on tiny particles with a diameter of 2.5 millionths of a meter, less than 1/30th the width of a human hair, referred to as PM2.5. These particles come from a variety of sources, including power plants, factories, trucks and automobiles, and can travel deep into the lungs.  They have been associated in previous studies with increased numbers of hospital visits for cardiovascular diseases, including heart attacks. “The link between increased stroke risk and these particulates can be observed within hours of exposure and are most strongly associated with pollution from local or transported traffic emissions,” said the … Continue reading

Comments Off on Moderate Air Pollution Linked To Stroke, Cognitive Decline

Neuralstem Announces Closing of $5.2-Million Registered Direct Offering

Posted: Published on February 14th, 2012

ROCKVILLE, Md., Feb. 14, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced today that it has closed on its previously announced registered direct placement of 5,200,000 shares of common stock at a price of $1.00 per share, and 5,200,000 warrants each with an exercise price of $1.02 per share and exercisable starting six months from the issuance date for a term of five years. The company received aggregate gross proceeds of $5,200,000, which will be used for general corporate purposes, including ongoing U.S. clinical trials. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) T.R. Winston & Company, LLC acted as the exclusive placement agent for the offering. About Neuralstem Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA. In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Neuralstem Announces Closing of $5.2-Million Registered Direct Offering

Velomedix Receives IDE Approval to Evaluate the Use of Rapid Therapeutic Hypothermia in the Management of AMI Patients

Posted: Published on February 14th, 2012

MENLO PARK, Calif.--(BUSINESS WIRE)-- Velomedix, Inc., a clinical stage medical device company advancing the field of therapeutic hypothermia, announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to evaluate the use of rapid therapeutic hypothermia for the treatment of patients suffering an acute myocardial infarction (AMI or heart attack). The conditional approval allows the company to initiate a clinical trial at select sites in the United States. Therapeutic hypothermia has been shown to significantly improve outcomes for several acute events such as cardiac arrest, heart attack, and acute ischemic stroke. It has also been used with great success for spinal cord injury. While there are several technologies currently being marketed for hypothermia management, Velomedix’s proprietary technology delivers unparalleled cooling speed and procedural efficiency that is expected to result in enhanced clinical outcomes and enable more widespread clinical adoption of this promising therapy. “While current technologies can reach a therapeutic target temperature of 33C in 1-2 hours, the Velomedix system has shown the ability to achieve 33C in less than 15 minutes,” commented Jeff Gold, President and CEO of Velomedix. “For AMI patients requiring an intervention to open a blocked artery, the ability … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Velomedix Receives IDE Approval to Evaluate the Use of Rapid Therapeutic Hypothermia in the Management of AMI Patients

Cleveland Clinic to Recruit Parkinson's Patients for 23andMe

Posted: Published on February 14th, 2012

By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) – Cleveland Clinic today said that it will recruit Parkinson's disease patients for 23andMe and the consumer genetics firm's ongoing research efforts in that area. The patients will be recruited to contribute their DNA to 23andMe's research database and complete online surveys regarding their health. Participants will be enrolled in 23andMe's Parkinson's Disease Research Community, enabling them to engage with other Parkinson's patients while getting full access to 23andMe's Personal Genome Service. Cleveland Clinic said the project is part of its own personalized healthcare initiative, which seeks to better predict risk for disease and response to therapies. "We are offering this opportunity to our patients because as part of our 'Patients First' mission, we feel it is an important collaboration that could lead to improvements in our ability to predict and treat Parkinson's disease," Kathryn Teng, director of the Center for Personalized Healthcare at Cleveland Clinic, said in a statement. 23andMe began a research collaboration in March 2009 with the Michael J. Fox Foundation for Parkinson's Research, and the Parkinson's Institute and Clinical Center aimed at enrolling 10,000 people to be part of its Parkinson's Disease Research Community. That collaboration led … Continue reading

Posted in Parkinson's Treatment | Comments Off on Cleveland Clinic to Recruit Parkinson's Patients for 23andMe

Page 7,136«..1020..7,1357,1367,1377,138..7,1507,160..»